This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma. ... DLBCL and PMBCL are both aggressive
The most common form of non-Hodgkin lymphoma (NHL), DLBCL accounts for about one in three cases of NHL. ... This was evaluated by the investigator using the Lugano Response Criteria for malignant lymphoma.
Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC). ... The study enrolled 587 patients aged from two to 21 years across 151 institutions who had previously untreated Hodgkin
BeiGene’s Brukinsa (zanubrutinib) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at ... BTK inhibitor for marginal zone lymphoma in
of investigational epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including DLBCL. ... large B-cell lymphoma and diffuse large B-cell lymphoma who have limited treatment options.
Moreover, improvements in EFS with Yescarta were consistent across key patient subgroups, including elderly patients, primary refractory patients, HGBL, and double-expressor lymphoma patients. ... DLBCL is the most common subtype of non-Hodgkin lymphoma
More from news
Approximately 9 fully matching, plus 222 partially matching documents found.
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....